» Articles » PMID: 38927436

The Role of Lipoprotein(a) in Peripheral Artery Disease

Overview
Journal Biomedicines
Date 2024 Jun 27
PMID 38927436
Authors
Affiliations
Soon will be listed here.
Abstract

Lipoprotein(a) is a low-density-lipoprotein-like particle that consists of apolipoprotein(a) bound to apolipoprotein(b). It has emerged as an established causal risk factor for atherosclerotic cardiovascular disease, stroke, and aortic valve stenosis through multifactorial pathogenic mechanisms that include inflammation, atherogenesis, and thrombosis. Despite an estimated 20% of the global population having elevated lipoprotein(a) levels, testing remains underutilized due to poor awareness and a historical lack of effective and safe therapies. Although lipoprotein(a) has a strong association with coronary artery disease and cerebrovascular disease, its relationship with peripheral artery disease is less well established. In this article, we review the epidemiology, biology, and pathogenesis of lipoprotein(a) as it relates to peripheral artery disease. We also discuss emerging treatment options to help mitigate major adverse cardiac and limb events in this population.

References
1.
. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007; 45(4):645-654. DOI: 10.1016/j.jvs.2006.12.054. View

2.
Waldmann E, Parhofer K . Lipoprotein apheresis to treat elevated lipoprotein (a). J Lipid Res. 2016; 57(10):1751-1757. PMC: 5036372. DOI: 10.1194/jlr.R056549. View

3.
Kamanna V, Kashyap M . Mechanism of action of niacin. Am J Cardiol. 2008; 101(8A):20B-26B. DOI: 10.1016/j.amjcard.2008.02.029. View

4.
Schmidt K, Noureen A, Kronenberg F, Utermann G . Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016; 57(8):1339-59. PMC: 4959873. DOI: 10.1194/jlr.R067314. View

5.
Nicholls S, Ditmarsch M, Kastelein J, Rigby S, Kling D, Curcio D . Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022; 28(8):1672-1678. DOI: 10.1038/s41591-022-01936-7. View